Shares of American Renal Associates Holdings Inc. (NYSE:ARA) traded up 3.3% during mid-day trading on Wednesday . The company traded as high as $24.19 and last traded at $23.51, with a volume of 116,237 shares changing hands. The stock had previously closed at $22.75.

A number of analysts have recently issued reports on the stock. SunTrust Banks Inc. assumed coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued a “buy” rating and a $34.00 price objective on the stock. Wells Fargo & Co. assumed coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued an “outperform” rating on the stock. Leerink Swann reiterated an “outperform” rating on shares of American Renal Associates Holdings in a report on Monday, May 16th. Goldman Sachs Group Inc. assumed coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Barclays PLC assumed coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued an “overweight” rating and a $33.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $31.80.

The firm has a 50-day moving average price of $0.00 and a 200 day moving average price of $0.00. The stock has a market cap of $528.37 million and a price-to-earnings ratio of 12.11.

American Renal Associates Holdings (NYSE:ARA) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.75) earnings per share for the quarter. The company earned $185.60 million during the quarter, compared to the consensus estimate of $161.50 million. Analysts anticipate that American Renal Associates Holdings Inc. will post $0.88 EPS for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.